|
Post by olderteampt on Feb 3, 2019 11:07:15 GMT -5
Pharmaceutical companies through history have shelfed products until they have exhausted the current system of what they see as maximized profits. Sanofi did this to MNKD and all the other BP's looked away to benefit as they too did not want to lose revenues all because patients on Afrezza have fewer ailments. The political environment surrounding diabetic medicines in terms of their costs, efficacy and public opinion is changing. In MNKD's case they have survived to this point. MNKD is in a different place now than it was upon FDA approval of Afrezza: MNKD now has more users(even if the numbers are small), Different management(which I consider better now with Mike C and an his newly acquired expert on the FDA and it's unique policies and political environment). MNKD now has UTHR at it's hip which has a management team with beliefs that is not like your typical big pharma. Pediatric trials are a heck of a lot closer to completion than they were upon FDA approval of Afrezza for adults. Today, Afrezza has better insurance coverage than it did upon FDA approval. Today, the FDA is beginning to acknowledge Afrezza in writing. Today, I am seeing more Afrezza commercials than I did back when Afrezza was approved. Today, more patients are wearing CGM's and they are seeing the benefits of Afrezza for themselves and showing their doctors the results. Now is not the time to sell Afrezza. Now is the time for Mike to build the best surrounding staff he can one day at a time. Mike has the best product and the best delivery mechanism to help the diabetic population across the globe. If Mike is the best manager he can be he will not sell Afrezza until he can maximize the profits and that is not anytime soon.
|
|
|
Post by mnholdem on Feb 3, 2019 12:02:57 GMT -5
Wow I just can’t believe anybody would say that after the United therapeutics deal🤷♀️ I thought it was most peoples opinion that it validated TS. At least Mike thinks Rothblatt is a big fan of what we are doing. Afrezza is a golden egg while Technosphere is the goose, IMO. Of course, MannKind hasn't taken that egg to the bank yet...
|
|
|
Post by rockstarrick on Feb 3, 2019 13:49:39 GMT -5
Wow I just can’t believe anybody would say that after the United therapeutics deal🤷♀️ I thought it was most peoples opinion that it validated TS. At least Mike thinks Rothblatt is a big fan of what we are doing. Afrezza is a golden egg while Technosphere is the goose, IMO. Of course, MannKind hasn't taken that egg to the bank yet... please don’t think I don’t have great expectations for Technosphere !! But if people can snub their nose at a drug like Afrezza, then they could certainly give TS the same treatment, or worse. I’m not saying this will happen, but it sure would be terrible if we found out this was the case, after we sold Afrezza. Inch by inch, step by step, Afrezza is on its way to profitability, I have little doubt that Afrezza will be successful, and result in the type of profitability that will allow mnkd to thrive, and Technosphere to grow. Afrezza will eventually fund the growth this great Company will need to ensure TS is not lost in the shuffle. We don’t want to sell Afrezza, not unless somebody is going to throw down a huge pile of Cash, plus hefty Royalties. Good Luck Everybody, Have a great Super Bowl Sunday !! ✌🏻😎
|
|
|
Post by sportsrancho on Feb 3, 2019 14:23:58 GMT -5
Nobody I know is snubbing their nose at Afrezza. I don’t know why you keep taking this to such an extreme. I believe Mike is completely committed to Afrezza’s success. We all know there isn’t a diabetic drug out there that can come close to it.
|
|
|
Post by peppy on Feb 3, 2019 14:31:53 GMT -5
Pharmaceutical companies through history have shelfed products until they have exhausted the current system of what they see as maximized profits. Sanofi did this to MNKD and all the other BP's looked away to benefit as they too did not want to lose revenues all because patients on Afrezza have fewer ailments. The political environment surrounding diabetic medicines in terms of their costs, efficacy and public opinion is changing. In MNKD's case they have survived to this point. MNKD is in a different place now than it was upon FDA approval of Afrezza: MNKD now has more users(even if the numbers are small), Different management(which I consider better now with Mike C and an his newly acquired expert on the FDA and it's unique policies and political environment). MNKD now has UTHR at it's hip which has a management team with beliefs that is not like your typical big pharma. Pediatric trials are a heck of a lot closer to completion than they were upon FDA approval of Afrezza for adults. Today, Afrezza has better insurance coverage than it did upon FDA approval. Today, the FDA is beginning to acknowledge Afrezza in writing. Today, I am seeing more Afrezza commercials than I did back when Afrezza was approved. Today, more patients are wearing CGM's and they are seeing the benefits of Afrezza for themselves and showing their doctors the results. Now is not the time to sell Afrezza. Now is the time for Mike to build the best surrounding staff he can one day at a time. Mike has the best product and the best delivery mechanism to help the diabetic population across the globe. If Mike is the best manager he can be he will not sell Afrezza until he can maximize the profits and that is not anytime soon. Quote: patients are wearing CGM's and they are seeing the benefits of Afrezza for themselves and showing their doctors the results. reply: This is the only reason MNKD hasn't been buried; We can see. People on Afrezza who were on RAA, say they feel better. We can see why. Afrezza RAA
|
|
|
Post by olderteampt on Feb 3, 2019 15:28:36 GMT -5
Peppy you picked out the most powerful line in my message above. If I were to make a commercial for Afrezza it would look like this,
AFREZZA, THE INSULIN THAT WORKS! COME SEE FOR YOURSELF. This would be in big bold letters across the screen. I would shows people of all races and different ages wearing their CGM machines all coming together holding hands in a long line and each individual would have a picture of their blood glucose readout by their body as you(Peppy) have shown above.
|
|
|
Post by stevil on Feb 3, 2019 15:42:52 GMT -5
Sports - hang in there. It has taken a really long time but the medical community is now just starting to feel the pressure of seeing BG numbers in real time. We all know there are only two ways to treat the post meal sugar spike; not eat the food; take the afrezza. Afrezza will have its day. It won't be in 6 months but Mike is making progress and so is Dave Kendall. At the same time CGM technology adoption is rapidly growing and costs are within reach of most even with no insurance. For $4 a day for the afrezza and $2.80 a day for a Libre sensor we are now under the price Kevin Johnson is selling a cup of coffee and a doughnut. In the mean time maybe Kevin with give us news on RLS to extend the runway. From someone with clinical experience, I don't fully agree with your post. I do agree that we're heading in that direction, but it will still likely be at least a couple years out. There are simply too many patients that cannot afford $7/day for insulin related expenses. Diabetes type 2 is significantly skewed towards those with less education and lower income levels. Also keep in mind that people with uncontrolled diabetes are not just on insulin. They are also at least on blood pressure, statins, and neuropathy pain meds. While none of those others are terribly expensive, it is not a cheap disease. Things will not change quickly unless/until Medicare and Medicaid programs start to accept Afrezza and it gets more accepted as the standard of care. Should be intuitive, but just in case it's not, the older you are, the higher chance you'll develop the disease. Medicare needs to jump on board and coverage for Afrezza is abysmal to non-existent. Medicare is covering CGMs, but it will likely take a couple years of seeing that injected insulin is still inadequate before looking for the solution. Your opinion vs mine, but from everything I've seen, pending some unforeseen circumstances, it will be another couple years minimum before I see traction really starting to change. MNKD still hasn't even fixed the awareness or perception of inhaled insulin yet. They're making strides, but without a mega budget to push it, it's not going to change soon. Expect a continually gradual slope like we've been seeing with a slightly steeper slope now that they're finally fueling the marketing machine. There are still too many barriers that need to be lifted. I don't know how much progress Mike has made with insurance companies, but after listening to his recent podcast, he didn't sound too optimistic about the changes. The TLDR version: it would be inappropriate to recommend MNKD as an investment based on Afrezza alone unless you want to put faith in a behind the scenes miracle... It's up to anyone to judge the risk/reward aspect for themselves, but for those expecting Afrezza to pave the way into the near future, I think they're going to be disappointed.
|
|
|
Post by mango on Feb 3, 2019 16:01:52 GMT -5
🤣
|
|
|
Post by peppy on Feb 3, 2019 16:47:08 GMT -5
Peppy you picked out the most powerful line in my message above. If I were to make a commercial for Afrezza it would look like this, AFREZZA, THE INSULIN THAT WORKS! COME SEE FOR YOURSELF. This would be in big bold letters across the screen. I would shows people of all races and different ages wearing their CGM machines all coming together holding hands in a long line and each individual would have a picture of their blood glucose readout by their body as you(Peppy) have shown above. oh, there are whole threads from after the sanofi drop, of me saying, for the ADA, get two people with continuous glucose monitors on a stage, one using afrezza, one using RAA. Have them dose as they would and eat, let the audience watch their continue glucose monitors. Whole Threads of me saying, we are not blind, we can see. Either the physicians are blind, stupid, or they don't care......... Or physicians have learned to fall in line...... part of training? Lying perfected..... until people have a "view to the kill." oh, I can see I am asking for trouble.
|
|
|
Post by mango on Feb 4, 2019 0:41:13 GMT -5
Peppy you picked out the most powerful line in my message above. If I were to make a commercial for Afrezza it would look like this, AFREZZA, THE INSULIN THAT WORKS! COME SEE FOR YOURSELF. This would be in big bold letters across the screen. I would shows people of all races and different ages wearing their CGM machines all coming together holding hands in a long line and each individual would have a picture of their blood glucose readout by their body as you(Peppy) have shown above. oh, there are whole threads from after the sanofi drop, of me saying, for the ADA, get two people with continuous glucose monitors on a stage, one using afrezza, one using RAA. Have them dose as they would and eat, let the audience watch their continue glucose monitors. Whole Threads of me saying, we are not blind, we can see. Either the physicians are blind, stupid, or they don't care......... Or physicians have learned to fall in line...... part of training? Lying perfected..... until people have a "view to the kill." oh, I can see I am asking for trouble. So peppy, my mom made a video the year I got married, she played it at a wedding reception, and it's like a slide show of me and these pictures from when I was baby to that present age (22), and Trouble by Ray LaMontagne is the soundtrack. Apparently it's my life's theme song. Seems to be your's too lol 🤣
|
|
|
Post by mango on Feb 4, 2019 4:28:42 GMT -5
Sports - hang in there. It has taken a really long time but the medical community is now just starting to feel the pressure of seeing BG numbers in real time. We all know there are only two ways to treat the post meal sugar spike; not eat the food; take the afrezza. Afrezza will have its day. It won't be in 6 months but Mike is making progress and so is Dave Kendall. At the same time CGM technology adoption is rapidly growing and costs are within reach of most even with no insurance. For $4 a day for the afrezza and $2.80 a day for a Libre sensor we are now under the price Kevin Johnson is selling a cup of coffee and a doughnut. In the mean time maybe Kevin with give us news on RLS to extend the runway. From someone with clinical experience, I don't fully agree with your post. I do agree that we're heading in that direction, but it will still likely be at least a couple years out. There are simply too many patients that cannot afford $7/day for insulin related expenses. Diabetes type 2 is significantly skewed towards those with less education and lower income levels. Also keep in mind that people with uncontrolled diabetes are not just on insulin. They are also at least on blood pressure, statins, and neuropathy pain meds. While none of those others are terribly expensive, it is not a cheap disease. Things will not change quickly unless/until Medicare and Medicaid programs start to accept Afrezza and it gets more accepted as the standard of care. Should be intuitive, but just in case it's not, the older you are, the higher chance you'll develop the disease. Medicare needs to jump on board and coverage for Afrezza is abysmal to non-existent. Medicare is covering CGMs, but it will likely take a couple years of seeing that injected insulin is still inadequate before looking for the solution. Your opinion vs mine, but from everything I've seen, pending some unforeseen circumstances, it will be another couple years minimum before I see traction really starting to change. MNKD still hasn't even fixed the awareness or perception of inhaled insulin yet. They're making strides, but without a mega budget to push it, it's not going to change soon. Expect a continually gradual slope like we've been seeing with a slightly steeper slope now that they're finally fueling the marketing machine. There are still too many barriers that need to be lifted. I don't know how much progress Mike has made with insurance companies, but after listening to his recent podcast, he didn't sound too optimistic about the changes. The TLDR version: it would be inappropriate to recommend MNKD as an investment based on Afrezza alone unless you want to put faith in a behind the scenes miracle... It's up to anyone to judge the risk/reward aspect for themselves, but for those expecting Afrezza to pave the way into the near future, I think they're going to be disappointed. You mention some very important issues, but diverted from one in particular. 99% of those who are managing people with T2D simply do not understand energy homeostasis and its role in health and disease. The SoC for T2D is medically incorrect and majority of physicians are prescribing harmful and dangerous drugs that are 100% medically incorrect. A diabetic state develops when there is a disruption of glucose homeostasis. In T2D we know the underlying defect is a diminished or loss of the first-phase insulin response. For reasons which remain unknown, this has gone ignored. Understanding glucose homeostasis and its role in diabetes is essential for understanding how to treat it. SGLT2 inhibitors prevent renal glucose reabsorption and cause glucose excretion in urine. This is abnormal and not reflective of proper bodily functioning. This is medically incorrect for the treatment of the person with T2D. I was talking with a nurse practitioner the other day, and she told me she can not ethically prescribe an SGLT2 inhibitor. The problem is not just all those things you mentioned, those are mainly side effects from us treating people with T2D medically incorrect to begin with. ADA is going in the opposite direction of logic and common sense.
|
|
|
Post by joeypotsandpans on Feb 4, 2019 5:03:37 GMT -5
Sports - hang in there. It has taken a really long time but the medical community is now just starting to feel the pressure of seeing BG numbers in real time. We all know there are only two ways to treat the post meal sugar spike; not eat the food; take the afrezza. Afrezza will have its day. It won't be in 6 months but Mike is making progress and so is Dave Kendall. At the same time CGM technology adoption is rapidly growing and costs are within reach of most even with no insurance. For $4 a day for the afrezza and $2.80 a day for a Libre sensor we are now under the price Kevin Johnson is selling a cup of coffee and a doughnut. In the mean time maybe Kevin with give us news on RLS to extend the runway. From someone with clinical experience, I don't fully agree with your post. I do agree that we're heading in that direction, but it will still likely be at least a couple years out. There are simply too many patients that cannot afford $7/day for insulin related expenses. Diabetes type 2 is significantly skewed towards those with less education and lower income levels. Also keep in mind that people with uncontrolled diabetes are not just on insulin. They are also at least on blood pressure, statins, and neuropathy pain meds. While none of those others are terribly expensive, it is not a cheap disease. Things will not change quickly unless/until Medicare and Medicaid programs start to accept Afrezza and it gets more accepted as the standard of care. Should be intuitive, but just in case it's not, the older you are, the higher chance you'll develop the disease. Medicare needs to jump on board and coverage for Afrezza is abysmal to non-existent. Medicare is covering CGMs, but it will likely take a couple years of seeing that injected insulin is still inadequate before looking for the solution. Your opinion vs mine, but from everything I've seen, pending some unforeseen circumstances, it will be another couple years minimum before I see traction really starting to change. MNKD still hasn't even fixed the awareness or perception of inhaled insulin yet. They're making strides, but without a mega budget to push it, it's not going to change soon. Expect a continually gradual slope like we've been seeing with a slightly steeper slope now that they're finally fueling the marketing machine. There are still too many barriers that need to be lifted. I don't know how much progress Mike has made with insurance companies, but after listening to his recent podcast, he didn't sound too optimistic about the changes. The TLDR version: it would be inappropriate to recommend MNKD as an investment based on Afrezza alone unless you want to put faith in a behind the scenes miracle... It's up to anyone to judge the risk/reward aspect for themselves, but for those expecting Afrezza to pave the way into the near future, I think they're going to be disappointed. stevil were your clinical rotations part of a city or county hospital and/or their outpatient clinics?
|
|
|
Post by falconquest on Feb 4, 2019 5:42:39 GMT -5
Last time we heard a "last post from me" title was LFD and we see where that went lol...you speak in terms of "our investment" and then give the ad nauseam cliche of defining insanity, well if you still own the stock after 11yrs. I guess by your own definition you're insane . Falconquest, last I remember you said you sold your position and were waiting to re-enter when you felt it was a better situation but yet you also speak in "our investment" terms... Got to love the half dozen or so "advisors" looking out for everyone's interest, don't recall meeting any of you at the last SH meetings... For whatever reasons folks originally or recently invested THEIR money into this founder/company they always had a choice...put their cash with a managed account advisor or via their own due diligence make an investment in something they personally believe in. Pretty sure most if not all are adults on here and think independently and that most if not all recognize the risk/reward scenarios involved with investing in upstart biotech companies. If not then by all means they've gotten the education of a lifetime. So where we have a group of financial advisors and Monday morning and/or armchair quarterbacks on here and you all know who you are, I think most longs here understand the current situation and can make their own decisions if they wish to continue to remain with their investment thesis or cut bait, but hey thanks for stopping by and as someone near and dear use to say...don't let the door slap you on the way out It isn't my desire to perpetually defend my position but since you mention me specifically I feel compelled. You are right that I sold my position. I exited at $0.46 which split adjusted today is $2.30. I did so because I watched the share price at the time in a state of perpetual decline. Quite frankly, I actually waited too long. I should have exited when it fell under a dollar. I was holding out hope that the free fall would stop. Hope is not a good investment strategy. I bought this stock to make money. That's the ONLY reason. When I realized that that simply wasn't going to happen I felt I had no choice but to get out. If you look at the share price performance since then (other than that weird manufactured blip to $6.00) I made a pretty good choice since as of Friday we sit at a split adjusted price of $0.268. Everyone has their own investment strategy and that was mine, revealed. I really don't care if anyone agrees with it or not. It has worked for me.
As some have stated this has become a "cult" stock. I don't necessarily agree with that characterization but when some push ideas like stock ownership as a qualification for posting on a message board and treating those who don't own shares as not being in the "club" it perpetuates that myth. I don't criticize anyone else's investment strategy and quite frankly if you look, I quite often wish current shareholders good luck. I do not speak in terms of "our investment". I have been fully up front with my position. You are right that I am waiting to re-enter however. I really believe Afrezza is a miracle drug and has the potential to substantially improve the lives of diabetics. Why else would I be here? I don't have time nor the interest in hanging out on a message board just to throw out contrarian opinions. If you don't agree with my opinions you are certainly welcome to debate them.
On the point of selling Afrezza, it may be a strategy for moving this company forward (maybe not, we can argue that) the argument for is that it relieves Mannkind of the financial burden of trying to market that drug. They would still make money from the manufacture of Afrezza and any sale could involve royalty payments that would add to the bottom line as well. I think if selling Afrezza gave them the cash to fully develop a non-opioid, rapid acting pain medication, they would reap huge financial gains. Isn't that a piece of the "embarrassment of riches" that Matt spoke of? That is one strategy for moving the company forward. Continuing to promote Afrezza and dare I say, hoping, that it pays off is another. Agree or disagree, it is simply one opinion against another. I have also stated in the past that I feel since I have been here for many, many years and that I have lost so much money on this stock that I have "earned" the right to be here (as have many others). I haven't read the rules of the board carefully but I don't believe they state that one must own shares to post here. My interest is in seeing this company thrive so i can get back in and make some money as was my original intention. I wish all current shareholders nothing but the best here with whatever strategy gets us (yes US) there.
|
|
|
Post by stevil on Feb 4, 2019 8:52:02 GMT -5
From someone with clinical experience, I don't fully agree with your post. I do agree that we're heading in that direction, but it will still likely be at least a couple years out. There are simply too many patients that cannot afford $7/day for insulin related expenses. Diabetes type 2 is significantly skewed towards those with less education and lower income levels. Also keep in mind that people with uncontrolled diabetes are not just on insulin. They are also at least on blood pressure, statins, and neuropathy pain meds. While none of those others are terribly expensive, it is not a cheap disease. Things will not change quickly unless/until Medicare and Medicaid programs start to accept Afrezza and it gets more accepted as the standard of care. Should be intuitive, but just in case it's not, the older you are, the higher chance you'll develop the disease. Medicare needs to jump on board and coverage for Afrezza is abysmal to non-existent. Medicare is covering CGMs, but it will likely take a couple years of seeing that injected insulin is still inadequate before looking for the solution. Your opinion vs mine, but from everything I've seen, pending some unforeseen circumstances, it will be another couple years minimum before I see traction really starting to change. MNKD still hasn't even fixed the awareness or perception of inhaled insulin yet. They're making strides, but without a mega budget to push it, it's not going to change soon. Expect a continually gradual slope like we've been seeing with a slightly steeper slope now that they're finally fueling the marketing machine. There are still too many barriers that need to be lifted. I don't know how much progress Mike has made with insurance companies, but after listening to his recent podcast, he didn't sound too optimistic about the changes. The TLDR version: it would be inappropriate to recommend MNKD as an investment based on Afrezza alone unless you want to put faith in a behind the scenes miracle... It's up to anyone to judge the risk/reward aspect for themselves, but for those expecting Afrezza to pave the way into the near future, I think they're going to be disappointed. stevil were your clinical rotations part of a city or county hospital and/or their outpatient clinics? All of the above. I’ve had the amazing opportunity to rotate at academic institutions, county, and rural locations. My school offered me both options- I could either stay within one system or I could travel and be apart of many. I chose to travel, hoping to see more pathology. There was one commonality amongst all locations. Afrezza was not on anyone’s immediate radar. More had heard of it than I was expecting (especially at the academic institutions... as you would hope) but there were few that had heard of it that wanted to learn more. I probably had the most success when I was able to present on Afrezza and really get into the details with mostly naive listeners, who were also predominantly residents, so that’s probably why - clean slates, so to speak. The old saying, “you only get one chance to make a first impression” is especially true in medicine. Once you learn something a certain way, it’s incredibly difficult to shake that understanding. Reason being, one needs to be confident in what they know as a doctor. You can’t second guess yourself or be unsure. That’s why I think it will take overwhelmingly convincing data to truly swing the pendulum, although it is obviously just my opinion. If I’m still being trained as a medical student after all these years that insulin is dangerous and should only be used as a last resort, think about the perception the docs have that used to prescribe nph insulin to their patients. An even bigger problem I’ve been seeing is that insulin is really getting blacklisted now with all the various other options. Treatment is heavily shifting towards GLP-1s, DPP-4s, SGLT2s, and the like since they’ve come out with various other benefits related to CVD and overall mortality. (And I’ve run out of stamina to argue them, so anyone- sayhey, mango, etc- go look them up for yourselves. I didn’t make up the data so i don’t want to defend it. It is what it is) Big pharma paid for those results. They compared them against insulin, so it will take a complete re-education of Afrezza insulin to prove why it’s different. This is where I think overwhelming data is needed. But that all takes a long time to test, compile, then publish. I’ve been waiting with bated breath for Dr. Kendall to show us something we haven’t seen yet, but he’s been eerily absent.
|
|
|
Post by peppy on Feb 4, 2019 9:57:13 GMT -5
quote from above, stevil said, "An even bigger problem I’ve been seeing is that insulin is really getting blacklisted now with all the various other options. Treatment is heavily shifting towards GLP-1s, DPP-4s, SGLT2s, and the like since they’ve come out with various other benefits related to CVD and overall mortality. (And I’ve run out of stamina to argue them, so anyone- sayhey, mango, etc- go look them up for yourselves. I didn’t make up the data so i don’t want to defend it. It is what it is) Big pharma paid for those results. They compared them against insulin, so it will take a complete re-education of Afrezza insulin to prove why it’s different. This is where I think overwhelming data is needed. But that all takes a long time to test, compile, then publish. I’ve been waiting with bated breath for Dr. Kendall to show us something we haven’t seen yet, but he’s been eerily absent." reply: Stevil, type one diabetes, Insulin is not optional is my understanding. Have things changed? How about LADA, any new orals or injectables for LADA? Type two's need to change the food attached to their fork. Any mention of that in medical school? eh? There seems to be plenty of people using fast acting insulin. 27 Apr 2018 Afrezza----495 $632k 277 $380k Apidra----6520 $4.95m 2254 $1.77m Novalog--137k $132m 56.0k $57.8m Humalog-151k $139m 60.3k $58.0m Humalin--37.4k $20.5m 14.9k $8.0m 1:06 PM - 11 May 2018
|
|